[en] Introduction: There is currently no diseasemodifying drug for osteoarthritis (OA), and
some safety concerns have been identified about the leading traditional drugs. Therefore,
research efforts have focused on alternatives such as supplementation with collagen derivatives. The objective of this scoping review is to examine the extent, range, and nature of research, and to summarize and disseminate research findings on the effects of collagen derivatives in OA and cartilage repair. The purpose is to identify gaps in the current body of
evidence in order to further help progress research in this setting.
Methods: The databases Medline, Scopus, CENTRAL, TOXLINE, and CDSR were comprehensively searched from inception to search date. After studies selection against eligibility criteria, following recommended methods, data were charted from the retrieved articles and these were subsequently synthesized. Numerical and graphical descriptive statistical methods were used to show trends in publications and geographical distribution of studies.
Results: The systematic literature search identified a total of 10,834 records. Forty-one published studies were ultimately included in the review, 16 of which were preclinical studies and 25 were clinical studies (including four systematic reviews/meta-analyses). Collagen hydrolysate (CH) and undenatured collagen (UC) were the two types of collagen derivatives
studied, with a total of 28 individual studies on CH and nine on UC. More than a third of
studies originated from Asia, and most of them have been published after 2008. Oral forms of
collagen derivatives were mainly studied; three in vivo preclinical studies and three clinical
trials investigated intra-articularly injected CH. In most of the clinical trials, treatment durations
varied between 3 and 6 months, with the shortest being 1.4 months and the longest 11 months. All in vivo preclinical studies and clinical trials, regardless of their quality, concluded on beneficial effects of collagen derivatives in OA and cartilage repair, whether used as
nutritional supplement or delivered intra-articularly, and whatever the manufacturers of the
products, the doses and the outcomes considered in each study.
Conclusions: Although current evidence shows some potential for the use of CH and UC as an
option for management of patients with OA, there is still room for progress in terms of laboratory and clinical research before any definitive conclusion can be made. Harmonization of
outcomes in preclinical studies and longer randomized placebo-controlled trials in larger
populations with the use of recommended and validated endpoints are warranted before collagen derivatives can be recommended by large scientific societies.
Disciplines :
Public health, health care sciences & services General & internal medicine
Author, co-author :
Honvo, Germain ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Lengele, Laetitia ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Charles, Alexia ; Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping
Vos T, Abajobir AA, Abbafati C, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59.
Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1323–30.
Bitton R. The economic burden of osteoarthritis. Am J Manag Care. 2009;15:S230–S235235.
Salmon JH, Rat AC, Sellam J, et al. Economic impact of lower-limb osteoarthritis worldwide: a systematic review of cost-of-illness studies. Osteoarthr Cartil. 2016;24:1500–8.
Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthr Cartil. 2013;21:1145–53.
Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185–99.
Berthelot G, Johnson S, Noirez P, et al. The age-performance relationship in the general population and strategies to delay age-related decline in performance. Arch Public Heal. 2019;77:1–9.
Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49:337–50.
Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr Cartil. 2019;27:1578–89.
Yusuf E. Pharmacologic and non-pharmacologic treatment of osteoarthritis. Curr Treat Options Rheumatol. 2016;2:111–25.
McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. 2014;22:363–88.
Bruyère O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44:253–63.
Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo-controlled trials. BMJ. 2015;350:h1225–h12251225.
Roberts E, Nunes VD, Buckner S, et al. Paracetamol: Not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016;75:552–9.
Olsen AMS, Fosbøl EL, Lindhardsen J, et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation. 2012;126:1955–63.
Curtis E, Fuggle N, Shaw S, et al. Safety of cyclooxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36:25–44.
Bruyere O, Reginster J. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging. 2007;24:573–80.
Reginster JY, Veronese N. Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res. 2020. 10.1007/s40520-020-01643-8. DOI: 10.1007/s40520-020-01643-8
Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin N Am. 1999;25:379–95.
Bello AE, Oesser S. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature. Curr Med Res Opin. 2006;22:2221–32.
Apostu D, Lucaciu O, Mester A, et al. Systemic drugs with impact on osteoarthritis. Drug Metab Rev. 2019;51:498–523.
Oesser S, Adam M, Babel W, Seifert J. Oral administration of 14C labeled gelatin hydrolysate leads to an accumulation of radioactivity in cartilage of mice (C57/BL). J Nutr. 1999;129:1891–5.
Yamamoto S, Deguchi K, Onuma M, Numata N, Sakai Y. Absorption and urinary excretion of peptides after collagen tripeptide ingestion in humans. Biol Pharm Bull. 2016;39:428–34.
Taga Y, Iwasaki Y, Shigemura Y, Mizuno K. Improved in vivo tracking of orally administered collagen hydrolysate using stable isotope labeling and LC–MS techniques. J Agric Food Chem. 2019;67:4671–8.
Bagi CM, Berryman ER, Teo S, Lane NE. Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat model of osteoarthritis (OA). Osteoarthr Cartil. 2017;25:2080–90.
Dai M, Sui B, Xue Y, Liu X, Sun J. Cartilage repair in degenerative osteoarthritis mediated by squid type II collagen via immunomodulating activation of M2 macrophages, inhibiting apoptosis and hypertrophy of chondrocytes. Biomaterials. 2018;180:91–103.
Van Vijven JPJ, Luijsterburg PAJ, Verhagen AP, van Osch GJVM, Kloppenburg M, Bierma-Zeinstra SMA. Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: a systematic review. Osteoarthr Cartil. 2012;20:809–21.
Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52:167–75.
Fuggle NR, Cooper C, Oreffo ROC, et al. Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clin Exp Res. 2020;32:547–60.
Honvo G, Reginster JY, Rabenda V, et al. Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36:65–99.
García-Coronado JM, Martínez-Olvera L, Elizondo-Omaña RE, et al. Effect of collagen supplementation on osteoarthritis symptoms: a meta-analysis of randomized placebo-controlled trials. Int Orthop. 2019;43:531–8.
Kloppenburg M, Kroon FPB, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78:16–24.
Bruyère O, Cooper C, Al-Daghri NM, Dennison EM, Rizzoli R, Reginster JY. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2018;30:111–7.
Honvo G, Bruyère O, Reginster JY. Update on the role of pharmaceutical-grade chondroitin sulfate in the symptomatic management of knee osteoarthritis. Aging Clin Exp Res. 2019;31:1163–7.
Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res. 2014;66:1844–55.
Honvo G, Bruyère O, Geerinck A, Veronese N, Reginster JY. Efficacy of chondroitin sulfate in patients with knee osteoarthritis: a comprehensive meta-analysis exploring inconsistencies in randomized, placebo-controlled trials. Adv Ther. 2019;36:1085–99.
Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13:141–6.
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol Theory Pract. 2005;8:19–32.
Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:1–9.
Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467–73.
Boonmaleerat K, Wanachewin O, Phitak T, Pothacharoen P, Kongtawelert P. Fish collagen hydrolysates modulate cartilage metabolism. Cell Biochem Biophys. 2018;76:279–92.
Furuzawa-Carballeda J, Muñoz-Chablé OA, Barrios-Payán J, Hernández-Pando R. Effect of polymerized-type I collagen in knee osteoarthritis. I. In vitro study. Eur J Clin Investig. 2009;39:591–7.
Schadow S, Siebert HC, Lochnit G, Kordelle J, Rickert M, Steinmeyer J. Collagen metabolism of human osteoarthritic articular cartilage as modulated by bovine collagen hydrolysates. PLoS ONE. 2013;8:e53955.
Schadow S, Simons VS, Lochnit G, et al. Metabolic response of human osteoarthritic cartilage to biochemically characterized collagen hydrolysates. Int J Mol Sci. 2017;18:207.
Dai M, Liu X, Wang N, Sun J. Squid type II collagen as a novel biomaterial: isolation, characterization, immunogenicity and relieving effect on degenerative osteoarthritis via inhibiting STAT1 signaling in pro-inflammatory macrophages. Mater Sci Eng C. 2018;89:283–94.
Dar QA, Schott EM, Catheline SE, et al. Daily oral consumption of hydrolyzed type 1 collagen is chondroprotective and antiinflammatory in murine posttraumatic osteoarthritis. PLoS ONE. 2017;12:1–24.
Di Cesare ML, Micheli L, Zanardelli M, Ghelardini C. Low dose native type II collagen prevents pain in a rat osteoarthritis model. BMC Musculoskelet Disord. 2013;14:228.
Hashida M, Miyatake K, Okamoto Y, et al. Synergistic effects of d-glucosamine and collagen peptides on healing experimental cartilage injury. Macromol Biosci. 2003;3:596–603.
Isaka S, Someya A, Nakamura S, et al. Evaluation of the effect of oral administration of collagen peptides on an experimental rat osteoarthritis model. Exp Ther Med. 2017;13:2699–706.
Nakatani S, Mano H, Sampei C, Shimizu J, Wada M. Chondroprotective effect of the bioactive peptide prolyl-hydroxyproline in mouse articular cartilage in vitro and in vivo. Osteoarthr Cartil. 2009;17:1620–7.
Naraoka T, Ishibashi Y, Tsuda E, Yamamoto Y, Kusumi T, Toh S. Periodic knee injections of collagen tripeptide delay cartilage degeneration in rabbit experimental osteoarthritis. Arthritis Res Ther. 2013;15:1–10.
Ohara H, Iida H, Ito K, Takeuchi Y, Nomura Y. Effects of Pro-Hyp, a collagen hydrolysate-derived peptide, on hyaluronic acid synthesis using in vitro cultured synovium cells and oral ingestion of collagen hydrolysates in a guinea pig model of osteoarthritis. Biosci Biotechnol Biochem. 2010;74:2096–9.
Ohnishi A, Osaki T, Matahira Y, et al. Evaluation of the chondroprotective effects of glucosamine and fish collagen peptide on a rabbit ACLT model using serum biomarkers. J Vet Med Sci. 2013;75:421–9.
Xu D, Shen W. Chicken collagen type II reduces articular cartilage destruction in a model of osteoarthritis in rats. West Indian Med J. 2007;56:202–7.
Bagchi D, Misner B, Bagchi M, Kothari SC, Downs BW, Preuss HG. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22:101–10.
Bakilan F, Armagan O, Ozgen M, Tascioglu F, Bolluk O, Alatas O. Effects of native type II collagen treatment on knee osteoarthritis: a randomized controlled trial. Eurasian J Med. 2016;48:95–101.
Benito-Ruiz P, Camacho-Zambrano MM, Carrillo-Arcentales JN, et al. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. Int J Food Sci Nutr. 2009;60:99–113.
Bernardo MLR, Azarcon AC. A randomized controlled trial on the effects of oral collagen treatment on the medial knee joint space and functional outcome among patients diagnosed with osteoarthritis of the knee. PARM Proc. 2012;4:1–8.
Crowley DC, Lau FC, Sharma P, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009;6:312–21.
Furuzawa-Carballeda J, Muñoz-Chablé OA, MacÍas-Hernández SI, Agualimpia-Janning A. Effect of polymerized-type i collagen in knee osteoarthritis. II. In vivo study. Eur J Clin Investig. 2009;39:598–606.
Jiang J-X, Zhou J-L, Prawitt J. Collagen peptides improve knee osteoarthritis in elderly women: a 6-month randomized, double-blind, placebo-controlled study. Agro FOOD Industry Hi Tech. 2014;25:19–23.
Kumar S, Sugihara F, Suzuki K, Inoue N, Venkateswarathirukumara S. A double-blind, placebo-controlled, randomised, clinical study on the effectiveness of collagen peptide on osteoarthritis. J Sci Food Agric. 2015;95:702–7.
Lee HS, Oh KJ, Moon YW, In Y, Lee HJ, Kwon SY. Intra-articular injection of type I atelocollagen to alleviate knee pain: a double-blind, randomized controlled trial. Cartilage. 2019. 10.1177/1947603519865304. DOI: 10.1177/1947603519865304
Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016;15:14.
Martin Martin LS, Massafra U, Bizzi E, Migliore A. A double blind randomized active-controlled clinical trial on the intra-articular use of Md-Knee versus sodium hyaluronate in patients with knee osteoarthritis (“Joint”). BMC Musculoskelet Disord. 2016;17:1–8.
McAlindon TE, Nuite M, Krishnan N, et al. Change in knee osteoarthritis cartilage detected by delayed gadolinium enhanced magnetic resonance imaging following treatment with collagen hydrolysate: a pilot randomized controlled trial. Osteoarthr Cartil. 2011;19:399–405.
Schauss AG, Stenehjem J, Park J, Endres JR, Clewell A. Effect of the novel low molecular weight hydrolyzed chicken sternal cartilage extract, biocell collagen, on improving osteoarthritis-related symptoms: a randomized, double-blind, placebo-controlled trial. J Agric Food Chem. 2012;60:4096–101.
Stančík R, Zvarka J, Hlaváč M, Kubinec V, Rovenský J. Collagen type I in the treatment of painful osteoarthritis of the knee. Reumatologia. 2012;50:390–6.
Trč T, Bohmová J. Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA). Int Orthop. 2011;35:341–8.
Azeem MA, Patil R. The study of undenatured type II collagen in the knee osteoarthritis. Int J Orthop Traumatol Surg Sci. 2019;5:172–5.
De Luca P, Colombini A, Carimati G, Beggio M, de Girolamo L, Volpi P. Intra-articular injection of hydrolyzed collagen to treat symptoms of knee osteoarthritis. A functional in vitro investigation and a pilot retrospective clinical study. J Clin Med. 2019;8:975.
Kilinc BE, Oc Y, Alibakan G, Bilgin E, Kanar M, Eren OT. An Observational 1-month trial on the efficacy and safety of Promerim for improving knee joint. Clin Med Insights Arthritis Musculoskelet Disord. 2018;11:1–4.
Mehra A, Anand P, Borate M, et al. A non-interventional, prospective, multicentric real life Indian study to assess safety and effectiveness of un-denatured type 2 collagen in management of osteoarthritis. Int J Res Orthop. 2019;5:315–20.
Puigdellivol J, Comellas Berenger C, Pérez Fernández MÁ, et al. Effectiveness of a dietary supplement containing hydrolyzed collagen, chondroitin sulfate, and glucosamine in pain reduction and functional capacity in osteoarthritis patients. J Diet Suppl. 2019;16:379–89.
Scarpellini M, Lurati A, Vignati G, et al. Biomarkers, type II collagen, glucosamine and chondroitin sulfate in osteoarthritis follow-up: the “Magenta osteoarthritis study”. J Orthop Traumatol. 2008;9:81–7.
de Silva V, El-Metwally A, Ernst E, Lewith G, Macfarlane GJ. Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. Rheumatology. 2011;50:911–20.
Yoshinari O, Marone PA, Moriyama H, Bagchi M, Shiojima Y. Safety and toxicological evaluation of a novel, water-soluble undenatured type II collagen. Toxicol Mech Methods. 2013;23:491–9.
Schauss AG, Merkel DJ, Glaza SM, Sorenson SR. Acute and subchronic oral toxicity studies in rats of a hydrolyzed chicken sternal cartilage preparation. Food Chem Toxicol. 2007;45:315–21.
Beynen AC, van Geene HW, Grim HV, Jacobs P, van der Vlerk T. Oral administration of gelatin hydrolysate reduces clinical signs of canine osteoarthritis in a double-blind, placebo-controlled trial. Am J Anim Vet Sci. 2010;5:95–9.
Gupta RC, Canerdy TD, Lindley J, et al. Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: Pain evaluation by ground force plate. J Anim Physiol Anim Nutr (Berl). 2012;96:770–7.
Stabile M, Samarelli R, Trerotoli P, et al. Evaluation of the effects of undenatured type II collagen (UC-II) as compared to robenacoxib on the mobility impairment induced by osteoarthritis in dogs. Vet Sci. 2019;6:72.
Bruyère O, Zegels B, Leonori L, et al. Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo-controlled study. Complement Ther Med. 2012;20:124–30.
Clark KL, Sebastianelli W, Flechsenhar KR, et al. 24-Week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint pain. Curr Med Res Opin. 2008;24:1485–96.
Lugo JP, Saiyed ZM, Lau FC, et al. Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Soc Sports Nutr. 2013;10:48.
Oesser S, Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Cell Tissue Res. 2003;311:393–9.
Ohara H, Matsumoto H, Ito K, Iwai K, Sato K. Comparison of quantity and structures of hydroxyproline-containing peptides in human blood after oral ingestion of gelatin hydrolysates from different sources. J Agric Food Chem. 2007;55:1532–5.
Walrand S, Chiotelli E, Noirt F, Mwewa S, Lassel T. Consumption of a functional fermented milk containing collagen hydrolysate improves the concentration of collagen-specific amino acids in plasma. J Agric Food Chem. 2008;56:7790–5.
Simons VS, Lochnit G, Wilhelm J, Ishaque B, Rickert M, Steinmeyer J. Comparative analysis of peptide composition and bioactivity of different collagen hydrolysate batches on human osteoarthritic synoviocytes. Sci Rep. 2018;8:1–10.
Nüesch E, Trelle S, Reichenbach S, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ. 2010;341:c3515.
Honvo G, Bannuru RR, Bruyère O, et al. Recommendations for the reporting of harms in manuscripts on clinical trials assessing osteoarthritis drugs: a consensus statement from the European Society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases. Drugs Aging. 2019;36:145–59.
